Mosliciguat
Small molecule
Also known as BAY 1211163
Evidence outlook · registrational
Pulmonary Hypertension Associated with Interstitial Lung Disease: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2029-01-28. The sponsor reported topline results of a Phase 2 study on 2026-09-08 (Phase 2 PHocus of inhaled mosliciguat in PH-ILD met its primary endpoint); that is not the registrational readout.
Latest reported trial: PHocus (NCT06635850) · Phase 2 · met primary endpoint · grade pending
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PHocus NCT06635850 · Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT06635850 | 2 | Change from Baseline to Week 16 in Pulmonary Vascular Resistance (PVR) (Baseline, Week 16) 2026-05-26 | PHocus (NCT06635850), primary endpoint change from baseline to Week 16 in pulmonary vascular resistance: placebo-adjusted reduction of -56.3% (p<0.0001); n=135. | not yet graded | link ↗ |
View 1 more trial
NCT07816185 NCT07816185 · Pulmonary Hypertension Associated with Interstitial Lung Disease Registry: NCT07816185 | 3 | Change from Baseline in 6-Minute Walk Distance (6MWD) (Baseline to Week 24) 2029-01-28 | In progress: results expected 28 Jan 2029 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other Soluble guanylate cyclase drugs
Riociguat, Vericiguat, Nurandociguat, Praliciguat, SK-08. Compare all 6 Soluble guanylate cyclase drugs
5 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Pulmonary Hypertension Associated with Interstitial Lung Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Mosliciguat: this drug | Phase 3 | Small molecule | Soluble guanylate cyclase | not yet graded | No reviewed efficacy summary in this indication | |
| Riociguat (Adempas) | Approved(overall) | Small molecule | Soluble guanylate cyclase | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso DPI) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | Reliable signal | NCT02630316: Change in peak 6-minute walk distance from baseline to week 16: inhaled treprostinil median +6.0 m vs placebo -9.0 m (n=163 each); Hodges-Lehmann difference 21.0 m (95% CI 7.0 to 37.0), p=0.0043 (CT.gov posted results). | |
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Vericiguat (Verquvo) | Approved(overall) | Small molecule | Soluble guanylate cyclase | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Treprostinil (L606) | Phase 3 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Fc-Relaxin Fusion Protein (TX45) | Phase 2 | Protein / enzyme therapeutic | Relaxin receptor (RXFP1) / relaxin | not yet graded | No reviewed efficacy summary in this indication | |
| LAM-001 | Phase 2 | Small molecule | mTOR (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| Mirivadelgat | Phase 2 | Small molecule | ALDH2 | not yet graded | No reviewed efficacy summary in this indication | |
| Nurandociguat | Phase 2(overall) | Small molecule | Soluble guanylate cyclase | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Praliciguat | Phase 2(overall) | Small molecule | Soluble guanylate cyclase | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| SK-08 | Phase 1(overall) | Small molecule | Soluble guanylate cyclase | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Mosliciguat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2029 (1)
January 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent